CompletedPHASE2, PHASE3NCT02858726
Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus
Studying Uremic pruritus
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cara Therapeutics, Inc.
- Principal Investigator
- Frederique Menzaghi, PhD, DDSCara Therapeutics
- Intervention
- CR845 0.5 mcg/kg(drug)
- Enrollment
- 226 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2016 – 2017
Study locations (26)
- Cara Therapeutics Investigator Site, Phoenix, Arizona, United States
- Cara Therapeutics Study Site, Pine Bluff, Arkansas, United States
- Cara Therapeutics Investigator Site, Long Beach, California, United States
- Cara Therapeutics Study Site, Northridge, California, United States
- Cara Therapeutics Study Site, Whittier, California, United States
- Cara Therapeutics Study Site, Denver, Colorado, United States
- Cara Therapeutics Study Site, Hollywood, Florida, United States
- Cara Therapeutics Study Site, Tampa, Florida, United States
- Cara Therapeutics Study Site, Winter Park, Florida, United States
- Cara Therapeutics Study Site, Augusta, Georgia, United States
- Cara Therapeutics Study Site, Meridian, Idaho, United States
- Cara Therapetics Study Site, Creve Coeur, Missouri, United States
- Cara Therapeutics Study Site, Kansas City, Missouri, United States
- Cara Therapeutics Study Site, Omaha, Nebraska, United States
- Cara Therapetics Investigator Site, Albuquerque, New Mexico, United States
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02858726 on ClinicalTrials.govOther trials for Uremic pruritus
Additional recruiting or active studies for the same condition.